ArticleOncology letters2025
Combination of immune checkpoint inhibitors and radiotherapy for bone metastases induces an abscopal effect and improves outcomes in non-small cell lung cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies.Frontiers in immunology · 2026Pooled it
- Prior curative-intent treatment strategy affects progression outcomes of first-line immunotherapy in metastatic non-small cell lung cancer: A retrospective cohort study.Experimental and therapeutic medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy (RT) improves outcomes in non-small cell lung cancer (NSCLC). However, the potential abscopal effect of RT for bone metastases (BoMs) remains unclear. The present retrospective study aimed to evaluate the impact of RT for BoMs on lung lesion response and survival in patients with NSCLC receiving ICIs. A total of 108 patients with NSCLC with BoMs treated with ICIs between March 2016 and January 2024 were included and divided into two groups based on whether they received RT for BoMs. Primary outcomes included the lung lesion response rate, overall survival (OS), progression-free survival (PFS) and incidence of immune-related adverse events (irAEs). Among 33 patients who received RT for BoM (RT-BoM group), the dose/fraction ranged from 2 to 8 Gy/1 to15 fx (total 8-39 Gy). The lung lesion response rate was significantly higher in the RT-BoM group than in the non-RT-BoM group (n=75; 42.4 vs. 21.3%; P=0.03). The median OS and PFS times were significantly longer in the RT-BoM group (24.9 vs. 16.3 months, P=0.01; 11.0 months vs. 6.2 months, P=0.03), while the incidence of irAEs was comparable (21.2 vs. 21.3%; P=0.99). The group that received RT before ICI initiation (n=22) had a significantly higher lung lesion response rate than the group that received RT after ICI initiation (n=11; 54.5 vs. 9.1%; P=0.02), with a trend toward prolonged OS and PFS. Multivariate analysis identified RT for BoMs as an independent predictor of lung response (P=0.02), OS (P=0.03) and PFS (P=0.02). RT for BoMs was associated with improved lung response and prognosis in patients with NSCLC receiving ICIs, suggesting a possible abscopal effect. Further validation in prospective studies with larger patient groups is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.